Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus total neoadjuvant chemoradiotherapy for pMMR/MSS locally advanced rectal cancer
ChiCTR2400079718Phase 2Recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Jan 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in rectal adenocarcinoma, sponsored by Yunnan Cancer Hospital. Primary endpoint: Pathological complete response rate. Started Jan 2024; status: recruiting.
02
Drugs
envafolimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400079718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079718.